BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21715183)

  • 1. Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer.
    Wozniak A
    Crit Rev Oncol Hematol; 2012 May; 82(2):200-12. PubMed ID: 21715183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging antiangiogenic therapies for non-small-cell lung cancer.
    Blakely C; Jahan T
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.
    Socinski MA
    Cancer Treat Rev; 2011 Dec; 37(8):611-7. PubMed ID: 21641723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic therapy in nonsmall cell lung cancer.
    Gutierrez M; Giaccone G
    Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile and tolerability of antiangiogenic agents in non-small-cell lung cancer.
    Gadgeel SM
    Clin Lung Cancer; 2012 Mar; 13(2):96-106. PubMed ID: 22056889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of antiangiogenic therapy in non-small cell lung cancer.
    Giaccone G
    Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BIBF 1120 for the treatment of non-small cell lung cancer.
    Reck M
    Expert Opin Investig Drugs; 2010 Jun; 19(6):789-94. PubMed ID: 20465363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting tumor neovasculature in non-small-cell lung cancer.
    Pallis AG; Syrigos KN
    Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.
    Reckamp KL
    Cancer Lett; 2012 Aug; 321(2):101-9. PubMed ID: 22306704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.
    Blackhall FH; Shepherd FA
    Hematol Oncol Clin North Am; 2004 Oct; 18(5):1121-41, ix. PubMed ID: 15474338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer.
    Nguewa PA; Calvo A; Pullamsetti SS; Banat GA; Grimminger F; Savai R
    Expert Opin Investig Drugs; 2011 Jan; 20(1):61-74. PubMed ID: 21142806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
    Ellis PM; Al-Saleh K
    Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer.
    Rolfo C; Raez LE; Bronte G; Santos ES; Papadimitriou K; Buffoni L; van Meerbeeck JP; Russo A
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1081-8. PubMed ID: 23790097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.
    Ulahannan SV; Brahmer JR
    Cancer Invest; 2011 May; 29(4):325-37. PubMed ID: 21469981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antivascular agents for non-small-cell lung cancer: current status and future directions.
    Amir E; Mandoky L; Blackhall F; Thatcher N; Klepetko W; Ankersmit HJ; Reza Hoda MA; Ostoros G; Dank M; Dome B
    Expert Opin Investig Drugs; 2009 Nov; 18(11):1667-86. PubMed ID: 19877762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer.
    Dowlati A
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S71-5. PubMed ID: 21885002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiangiogenic agents: current limits in thoracic oncology].
    Dansin E; Lauridant G; Chahine B
    Bull Cancer; 2012 Nov; 99(11):1083-91. PubMed ID: 23113985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future strategies for antiangiogenic agents in non-small-cell lung cancer.
    Herbst RS
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S50. PubMed ID: 21884998
    [No Abstract]   [Full Text] [Related]  

  • 19. Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer.
    Bertino EM; Otterson GA
    Lung Cancer; 2010 Dec; 70(3):233-46. PubMed ID: 20888062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The actual place of anti-angiogenesis in non-small cell lung cancer].
    Mennecier B
    Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S198-205. PubMed ID: 18235414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.